AMPLIA THERAPEUTICS LTD.
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).
AMPLIA THERAPEUTICS LTD.
Industry:
Pharmaceutical Therapeutics
Founded:
2016-01-01
Address:
North Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.ampliatx.com
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Google Font API Google Tag Manager Google Analytics Font Awesome Global Site Tag HSTS ReCAPTCHA Google Universal Analytics
Similar Organizations
Amrita Therapeutics
Amrita Therapeutics is a biopharmaceutical company.
Cannpal Animal Therapeutics
Cannpal Animal Therapeutics is an Australia-based pet pharmaceutical company.
Northern Therapeutics
Northern Therapeutics is a biopharmaceutical company
Orpharma
Orpharma is an Australian pharmaceutical company.
TAP Pharmaceuticals
TAP Pharmaceuticals was an American pharmaceutical company.
Current Employees Featured
Official Site Inspections
http://www.ampliatx.com Semrush global rank: 5.74 M Semrush visits lastest month: 1.24 K
- Host name: a290d26420470737c.awsglobalaccelerator.com
- IP address: 15.197.133.181
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Amplia Therapeutics Ltd."
About Us | Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly โฆSee details»
Annual Report - ampliatx.com
Mar 31, 2022 Website www.ampliatx.com Corporate Directory. 6 Amplia Therapeutics Limited Directorsโ Report for the year ended 31 March 2022 Your directors present their report on โฆSee details»
Amplia Therapeutics Ltd. - Crunchbase Company Profile & Funding
Contact Email [email protected] Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and โฆSee details»
Amplia Therapeutics Company Description - Stock Analysis
Sep 24, 2024 Company profile for Amplia Therapeutics Limited (ASX: ATX) with a description, list of executives, contact details and other key facts.See details»
Amplia Therapeutics Limited - LinkedIn
Amplia Therapeutics Limited | 1,724 followers on LinkedIn. Amplifying Oncology Treatments | Despite the recent success of immuno-oncology drugs, their use in fibrotic cancers โฆSee details»
Amplia Therapeutics Ltd. - Drug pipelines, Patents, Clinical
For more information visit and follow Amplia on Twitter (@ampliatx), Threads (@ampliatx) and LinkedIn. SOURCE Amplia Therapeutics. Phase 2 IND. 09 Oct 2023 ... The statistics for drugs โฆSee details»
Amplia Therapeutics Ltd. (Amplia Therapeutics Ltd.) - ่ฏ็ฉ็ฎก็บฟ_ไธ โฆ
Abstract Amplia Therapeutics Limited is developing AMP945, a highly selective inhibitor of Focal adhesion kinase (FAK) for the treatment of pancreatic cancer in combination with standard of โฆSee details»
Amplia Therapeutics - Overview, News & Similar companies
Amplia Therapeutics contact info: Phone number: +61 391231140 Website: www.ampliatx.com What does Amplia Therapeutics do? Amplia Therapeutics Limited is an Australian โฆSee details»
FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER โฆ
Jan 18, 2024 Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce that the US FDA have cleared Amplia's IND application for a trial of Amplia's best โฆSee details»
Investor Centre - Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly โฆSee details»
Fifth Confirmed Response in ACCENT Trial
Aug 21, 2024 ABN 16 165 160 841 Level 17, 350 Queen Street, Melbourne VIC 3000 Email [email protected] www.ampliatx.com ASX RELEASE 21 August 2024 FIVE PATIENTS โฆSee details»
Amplia Therapeutics (@ampliatx) โข Threads, Say more
Nov 13, 2024 3 Followers โข 0 Threads โข Amplia Therapeutics Limited is a pharmaceutical company advancing a pipeline of FAK inhibitors for cancer and fibrosis. See the latest โฆSee details»
Amplia Therapeutics Ltd (asx:ATX) Share Price | Morningstar
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play โฆSee details»
Amplia reports first patient dosing in Phase 2a ACCENT trial
Jan 17, 2024 For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx), Threads (@ampliatx) and LinkedIn. Contacts Investor contact Dr Chris Burns โฆSee details»
FDA clearance of Amplia's IND for pancreatic cancer trial in US
Jan 17, 2024 Amplia Therapeutics Limited is pleased to announce that the US FDA have cleared Amplia's IND application for a trial of Amplia's best-in-class focal adhesion kinase (FAK) โฆSee details»
2021 Annual General Meeting CEO Presentation - Amplia โฆ
Email [email protected]. www.ampliatx.com . ASX RELEASE 27 August 2021 . Annual General Meeting โ CEO Presentation . Amplia Therapeutics Limited (ASX: ATX) (โAmpliaโ or the โฆSee details»
FDA Fast Track Designation granted to narmafotinib in pancreatic โฆ
Sep 20, 2024 FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow โฆSee details»
Texas GOP donor spends $20 million on new PAC | The Texas โฆ
Alex Fairly is an Amarillo businessman and father of a state House member who has previously given millions to West Texas A&M University, Lt. Gov. Dan Patrick and Attorney General Ken โฆSee details»
Copy of Amplia EOY Update 2022 - Amplia Therapeutics Limited
Ampliatx.com 2022 Year in Review and Growth Plans for 2023 December 2022 . Important Notice and Disclaimer AmpliQ This presentation (Presentation) contains summary information about โฆSee details»
Three major MGA organizations to merge - insuranceinstitute.ca
Dec 10, 2024 Each brand will continue to operate with the same leadership and focus on marketplace niches, backed by the resilience and governance of a larger organization. โThe โฆSee details»